Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 1116
  • Home
  • Print this page
  • Email this page
CASE REPORT
Year : 2020  |  Volume : 68  |  Issue : 11  |  Page : 2569-2572

Role of secukinumab in ankylosing spondylitis with tubercular uveitis


1 Department of Uveitis and Ocular Immunology Services, Narayana Nethralaya, Bangalore, Karnataka, India
2 Department of Clinical Immunology and Rheumatology, Bhagwan Mahavir Jain Hospital, Bangalore, Karnataka, India
3 Department of Cataract, Narayana Nethralaya, Bangalore, Karnataka, India

Correspondence Address:
Dr. Padmamalini Mahendradas
Narayana Nethralaya, 121/C, Chord Road, Rajajinagar, 1st ‘R’ Block, Bangalore - 560 010, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijo.IJO_1081_20

Rights and Permissions

We present the case of a 32-year-old Indian male one-eyed individual with a history of unilateral panuveitis with HLA B 27 positive spondyloarthropathy on systemic immunosuppressant (Adalimumab). He developed recurrent inflammation in the same eye in a span of 2 years, later complicated with retinal vasculitis. On evaluation, he was diagnosed with tubercular uveitis and started on antitubercular treatment along with systemic steroids. Inview of Increased IOP due to steroid response, Inj. Secukinumab ( IL 17 A inhibitor) was started and significant improvement was noted.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed383    
    Printed0    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal